Attached files
| file | filename |
|---|---|
| EX-99.1 - NOVAVAX INC | v192705_ex99-1.htm |
| EX-99.2 - NOVAVAX INC | v192705_ex99-2.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported) August 6, 2010
NOVAVAX,
INC.
(Exact
name of Registrant as specified in its charter)
|
Delaware
|
0-26770
|
22-2816046
|
||
|
(State
or other jurisdiction of incorporation or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
9920
Belward Campus Drive
Rockville,
Maryland
|
20850
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
|
Registrant’s
telephone number, including area code:
|
(240)
268-2000
|
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2.
below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02 Results of Operations and Financial Condition.
On August
6, 2010, Novavax, Inc. (the “Company”) announced its financial results for the
second quarter ended June 30, 2010 and will conduct a previously announced,
publicly available conference call to discuss those results as well as to
provide an update on the status of the Company's business
operations.
The
Company issued a press release announcing its financial results on August 6,
2010. A copy of the press release is filed with this report as
Exhibit 99.1.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On August
6, 2010, the Board of Directors of the Company elected Richard H. Douglas, Ph.D.
as a Class II director, effective immediately. Dr. Douglas is an
independent director, as defined by the NASDAQ Listing Rules. Dr.
Douglas was not elected pursuant to any arrangement or understanding between him
and any other person and has not been appointed to serve on any committees of
the Board of Directors at this time.
The
Company issued a press release announcing the election of Dr. Douglas on August
6, 2010. A copy of that press release is filed with this report as
Exhibit 99.2.
The
information furnished in this Current Report on Form 8-K and Exhibits
99.1 and 99.2 attached hereto shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor
shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, except as shall be expressly set forth by specific
reference in such filing.
Item
9.01. Financial Statements and Exhibits.
|
(d)
|
Exhibits
|
Exhibits
|
|
99.1
|
Press
release issued by Novavax, Inc. related to Earnings on August 6,
2010
|
|
|
99.2
|
Press
release issued by Novavax, Inc. related to Dr. Douglas on August 6,
2010
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized
|
Novavax,
Inc.
(Registrant)
|
||||||||
|
August
6, 2010
|
By:
|
/s/ John A. Herrmann
III
|
||||||
|
Name:
|
John
A. Herrmann III
|
|||||||
|
Title:
|
Executive
Director, Legal Affairs and Corporate Secretary
|
|||||||